NASDAQ: LUCDLucid Diagnostics Inc Stock
$1.39+0.11 (+8.59%)
Updated Mar 14, 2025
LUCD Price
$1.39
Fair Value Price
$0.29
Market Cap
$82.49M
52 Week Low
$0.63
52 Week High
$1.63
P/E
-1.23x
P/B
13.01x
P/S
9.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.19M
Earnings
-$44.82M
Gross Margin
-53%
Operating Margin
-1,069.18%
Profit Margin
-1,248.8%
Debt to Equity
2.57
Operating Cash Flow
-$44M
Beta
0.84
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LUCD Overview
Lucid Diagnostics Incorporated is developing products to diagnose and treat conditions of the esophagus, including conditions arising from chronic heartburn which may lead to esophageal cancer. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test, and EsoCheck, an esophageal cell collection device. Lucid Diagnostics was incorporated in 2018 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LUCD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important LUCD news, forecast changes, insider trades & much more!
LUCD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LUCD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LUCD ($1.39) is overvalued by 383.23% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LUCD ($1.39) is not significantly undervalued (383.23%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LUCD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LUCD due diligence checks available for Premium users.
Valuation
LUCD fair value
Fair Value of LUCD stock based on Discounted Cash Flow (DCF)
Price
$1.39
Fair Value
$0.29
Overvalued by
383.23%
LUCD ($1.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LUCD ($1.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LUCD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LUCD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.23x
Industry
41.08x
Market
3,446.57x
LUCD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.01x
Industry
3.94x
LUCD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LUCD's financial health
Profit margin
Revenue
$1.2M
Net Income
-$12.4M
Profit Margin
-1,055.5%
LUCD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUCD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.6M
Liabilities
$16.3M
Debt to equity
2.57
LUCD's short-term assets ($16.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUCD's short-term assets ($16.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUCD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
-$350.0k
Financing
$94.0k
LUCD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LUCD vs Medical Device Stocks
Lucid Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.